DDi's TULA & CM is selected by Asia Pharma Major for Oversight and RBM
10/19/2016

A TOP 3 Asia HQ pharma company signed selected TULA & CM for Oversight and RBM with DDi.

Online PR News – 19-October-2016 – New Jersey , USA – DDi the eclinical and technology partner of pharma and Biotech companies is selected by Asia Pharma Major for Clinical Oversight and RBM.Clinical analytics (ClinMetanoia) and and vendor oversight risk management (TULA) are provided by DDi with customized dashboard and action oriented triggers and reports.

With strong recommendations from regulatory agencies and in response to increasing complexity, cost of clinical trials, the biopharma companies are actively looking into implementing new monitoring initiatives like Risk-Based Monitoring (RBM), Centralized Monitoring to their clinical studies to ensure quality, compliance, patient safety and oversight. While the trend in implementing these new monitoring approaches has been more in US and EU pharma, companies in Asia are equally adapting and implementing these while highly motivated to make these programs successful.

For more info : http://bit.ly/2edwOEU